Carregant...
Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure based drug design
[Image: see text] CXCL12 is an attractive target for clinical therapy because of its involvement in autoimmune diseases, cancer growth, metastasis, and neovascularization. Tyrosine sulfation at three positions in the CXCR4 N-terminus is crucial for specific, high-affinity CXCL12 binding. An NMR stru...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2941798/ https://ncbi.nlm.nih.gov/pubmed/20459090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ja1002263 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|